NICE recommends Simponi for Ulcerative Colitis-Merck
In its Final Appraisal Document, NICE recommends approval of Simponi (golimumab), from Merck Inc, within its marketing authorisations, as options for treating moderately to severely active Ulcerative Colitis (UC) in adults whose disease has responded inadequately to conventional therapy including corticosteroids and mercaptopurine. In September 2014 NICE announced that there was not enough evidence to show it is clinically and cost effective compared with other therapies currently available but began a consultation period.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins